Loughborough University The Centre for Biological Engineering	Acquisition and Receipt of Biological Materials						
Doc Ref: FS008.1 : HTA-PR-FORM/007	Version N°:	1.0	Issue Date:				

ARF No: CBE/ARF/000 55 55

PART A: To be completed by the	Receiv	er (a separate	form must be o	completed for e	each sample t	ype)	
A1. Details of Sample/Specimen							
Type/ID: (eg primary cell, cell line, tissufluid, excreta, biological agent)	ie, body	Fibroblasts	Fibroblasts				☑Human □Animal
Format / Quantity: (eg vials, slides, e	etc)	3 Vials					
Tissue site/Organ source:		Skin				□N/A	
Batch N°:		C-12200					
Is the sample/specimen consider If No, go to section A2.	ed to b	be Relevant Material under the Human Tissue Act (HTA)?					☑Yes □No
the material obtained from an HTA licenced Tissue Bank with REC approval for generic research use?						☑Yes □No	
Is the material obtained for storage and use under a project specific NHS REC approval?					□Yes □No		
Is the material licensable under t	the material licensable under the HTA? Indicate source below:					☑Yes □No	
☑HTA licensed organisation ☑Commercial Supplier ☑ Imported (from outside England, Wales or N.Ireland)							
If Yes, list lot numbers (or other identifier) & the corresponding assigned unique sample ID		Lot N°: SV-F21-017, SV-F21-018, SV-F21-019 Assigned Unique ID (Pro			nique ID (Proc	uro):	
If Yes, provide Project Ref N°:		'Proof of concept for separation of young from old (senescent) cells – improvi					
If Yes, provide the name of the P	l:	Alexandra Stolzing					
A2. Details of Receipt							
Date/Time of receipt		Date	te 30/06/21		Time:	12:30	
ID of Receiver		Name:	Kul		Dept:	CBE	
ID of Supplier/Provider		Name:	ame: Stemnovate		Country:	UK	
PART B: To be completed by the	Receiv	er					
B1. Inspection and Quarantine							
Has a biological risk assessment for the use of this material been approved?		☑Yes □No	Ref Number: CBE-199				
Physical integrity of the material(s) acceptable?		☑Yes □No	If No, describ	If No, describe action taken			
Quantity received correct?		☑Yes □No	If No, describe action taken				
Labelling correct and legible?		☑Yes □No	If No, describe action taken				
If No. add reference or details material eg MTA,		У	t evidence of Yes \(\subseteq \text{No } \(\subseteq \)				
				□Yes □No ☑N/A			
		s/evidence/assurance of nt		☑Yes □No □	□N/A		

	Other (describe)	Yes □No ☑N/A					
Temporary storage - Quarantine location (as applicable)	Building/Room		CBE				
	Storage Unit ID		Bank 7				
	Within storage u	nit location ID	Rack 5, Box B, Positions 6,7,8				
	Date/Time of qu	arantine	24/06/21				
Submitted by:	Signature:		Date: 30/06/21				
	1 200	1200					
PART C: To be completed by the	departmental Qu	ality Manager					
C1. Quality Assurance Checks				☑Yes □No □N/A			
Has the sample/specimen been s	creened for infect	ious biological agen	ts?	•			
Has the donor been screened for		☑Yes □No □N/A					
Has the sample/specimen been s	☑Yes □No □N/A						
Is there evidence that the supplie or other recognised certification?	☑Yes □No □N/A						
For HTA licensable material, is the and use of the material under the	☑Yes □No □N/A						
Is there sufficient evidence to sup	□Yes □No ☑N/A						
C2. Approval for release from quarantine							
Can the material be released from released for processing?	nated storage area or	☑Yes □No					
If No, provide recommendations for deposition of the material and the results of any action relating to non-conforming material.		☐ Accept as is, but with extra controls					
		☐ Rework or repro					
		☐Test to meet specified requirements					
relating to non-comorning mater	itai.	☐Return to suppl	ier/provider				
	□Disposal						
		Building/Room		H25			
If Yes, provide details of storage loapplicable)		Storage Unit ID					
	ocation (as	Within storage unit location ID					
		Database Reference					
		Date/Time of tran	sfer				
Approved by:		Signature: C.Kava	anagh	Date: 05.07.2021			